

10/038,112

=> d his

(FILE 'HOME' ENTERED AT 21:22:51 ON 07 JUN 2004)

FILE 'REGISTRY' ENTERED AT 21:23:17 ON 07 JUN 2004

L1 STRUCTURE UPLOADED  
L2 0 S L1 SSS SAM  
L3 18 S L1 SSS FULL

FILE 'HCAPLUS, USPATFULL, MEDLINE, BIOSIS, EMBASE' ENTERED AT 21:24:29 ON 07 JUN 2004

L4 73 S L3  
L5 5 S L4 AND GLAUCOM?  
L6 5 DUP REM L5 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 21:26:55 ON 07 JUN 2004

FILE 'HCAPLUS, USPATFULL, MEDLINE, BIOSIS, EMBASE' ENTERED AT 21:32:04 ON 07 JUN 2004

L7 11 S L4 AND (OCULAR? OR INTRAOCULAR? OR INTRA(2A)OCULAR? OR OPHTHA  
L8 11 DUP REM L7 (0 DUPLICATES REMOVED)

=> s 18 not 16

L9 6 L8 NOT L6

=> d 19 abs ibib kwic hitstr 1-6

L9 ANSWER 1 OF 6 USPATFULL on STN

AB The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain useful agents are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:45081 USPATFULL

TITLE: Preventing and reversing the formation of advance glycosylation endproducts

INVENTOR(S): Cerami, Anthony, Shelter Island, NY, UNITED STATES  
Ulrich, Peter C., Old Tappan, NJ, UNITED STATES  
Wagle, Dilip R., Valley Cottage, NY, UNITED STATES  
Hwang, San-Bao, Sudbury, MA, UNITED STATES  
Vasan, Sara, Yonkers, NY, UNITED STATES  
Egan, John J., Mountain Lakes, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004034074	A1	20040219
APPLICATION INFO.:	US 2003-418398	A1	20030418 (10)

DELACROIX

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-174883, filed on 19 Jun 2002, PENDING Division of Ser. No. US 1999-470482, filed on 22 Dec 1999, GRANTED, Pat. No. US 6440749 Division of Ser. No. US 1997-971878, filed on 19 Nov 1997, GRANTED, Pat. No. US 6007865 Division of Ser. No. US 1996-588249, filed on 18 Jan 1996, GRANTED, Pat. No. US 5853703 Continuation-in-part of Ser. No. US 1995-473184, filed on 7 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1995-375155, filed on 18 Jan 1995, GRANTED, Pat. No. US 5656261

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 2067

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CLM What is claimed is:

6. A composition for **ocular** administration comprising 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride.

IT	4568-71-2P	5304-34-7P	6274-00-6P	7467-00-7P	7478-09-3P
	16311-69-6P	52197-73-6P	53995-67-8P	54016-70-5P	57132-40-8P
	57168-49-7P	57168-62-4P	61544-06-7P	74360-51-3P	74385-09-4P
	87910-71-2P	97380-14-8P	121704-45-8P	132416-79-6P	138404-41-8P
	159356-41-9P	181069-78-3P	181069-79-4P	<b>181069-80-7P</b>	
	181069-81-8P	181069-82-9P	181069-83-0P	<b>181069-84-1P</b>	
	181069-85-2P	181069-86-3P	181069-89-6P	181069-90-9P	181069-91-0P
	181069-92-1P	181069-93-2P	181069-95-4P	181069-96-5P	181069-98-7P
	181069-99-8P	181070-00-8P	181070-03-1P	181070-04-2P	181070-05-3P
	181070-06-4P	181070-07-5P	181070-08-6P	181070-09-7P	181070-10-0P
	181070-11-1P	181070-12-2P	181070-13-3P	181070-14-4P	181070-15-5P
	181070-16-6P	181070-18-8P	181070-22-4P	181070-24-6P	181070-25-7P
	181070-26-8P	181070-27-9P	181070-28-0P	181070-29-1P	181070-30-4P
	181070-31-5P	181070-33-7P	181070-35-9P	181070-36-0P	181070-37-1P
	181070-38-2P	181070-39-3P	181070-40-6P	181070-41-7P	181070-43-9P
	181070-44-0P	181070-46-2P	181070-48-4P	181070-49-5P	181070-50-8P
	181070-51-9P	181070-52-0P	181070-53-1P	181070-54-2P	181070-55-3P
	<b>181070-56-4P</b>	181070-57-5P	181070-58-6P	181070-59-7P	
	181070-60-0P	181070-61-1P	181070-62-2P	181070-63-3P	181070-64-4P
	181070-65-5P	181070-66-6P	181070-67-7P	181070-68-8P	181070-69-9P
	181070-70-2P	181070-71-3P	181070-72-4P	181070-74-6P	181147-74-0P

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)


IT **181069-80-7P 181069-84-1P 181070-56-4P**

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

RN 181069-80-7 USPATFULL

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, bromide (9CI) (CA INDEX NAME)


10/038,112



● Br<sup>-</sup>

RN 181069-84-1 USPATFULL

CN Thiazolium, 3-[2-(4-bromophenyl)-2-oxoethyl]-4,5-dimethyl-, bromide (9CI)  
(CA INDEX NAME)




● Br<sup>-</sup>

RN 181070-56-4 USPATFULL

CN Thiazolium, 3-[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-oxoethyl]-4,5-dimethyl-, bromide (9CI) (CA INDEX NAME)

DELACROIX



● Br<sup>-</sup>

L9 ANSWER 2 OF 6 USPATFULL on STN

AB The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:311845 USPATFULL  
 TITLE: 3-deoxyglucosone and skin  
 INVENTOR(S): Tobia, Annette, Wyndmoor, PA, UNITED STATES  
 Kappler, Francis, Philadelphia, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219440	A1	20031127
APPLICATION INFO.:	US 2002-198706	A1	20020718 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-392530P	20020627 (60) /
	US 2002-373103P	20020417 (60) /

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
 PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 216  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 11 Drawing Page(s)  
 LINE COUNT: 5483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . invention may be administered, prepared, packaged, and/or sold  
 in formulations suitable for oral, rectal, vaginal, parenteral, topical,

DELACROIX

pulmonary, intranasal, buccal, **ophthalmic**, or another route of administration. Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient, and. . .

DETD . . . may be administered via numerous routes, including, but not limited to, oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, or **ophthalmic** administration routes. The route(s) of administration will be readily apparent to the skilled artisan and will depend upon any number. . .

DETD [0352] Pharmaceutical compositions that are useful in the methods of the invention may be administered systemically in oral solid formulations, **ophthalmic**, suppository, aerosol, topical or other similar formulations. In addition to the compound such as heparan sulfate, or a biological equivalent. . .

DETD . . . the invention may be prepared, packaged, or sold in formulations suitable for oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, **ophthalmic**, intrathecal or another route of administration. Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient. . .

IT 52-66-4, DL-Penicillamine 52-67-5, D-Penicillamine 54-96-6,  
3,4-Diaminopyridine 56-03-1, Imidodicarbonimidic diamide 93-64-1  
95-02-3, 4-Amino-5-aminomethyl-2- methylpyrimidine 102-02-3 118-70-7,  
4,5,6-Triaminopyrimidine 452-58-4, 2,3-Diaminopyridine 459-86-9,  
Methylglyoxal bis(guanyldihydrazone) 553-83-3 584-13-4,  
4H-1,2,4-Triazol-4-amine 618-77-9 619-05-6 657-24-9 875-55-8  
921-52-8, 2,3-Diaminosuccinic acid 1004-38-2, 2,4,6-Triaminopyrimidine  
1004-75-7, 2,4,5- Triamino-6-hydroxypyrimidine 1113-41-3,  
L-Penicillamine 1672-50-0, 4,5-Diamino-6-hydroxy pyrimidine 1945-65-9  
2434-56-2, 4,6- Diaminopyrimidine 3357-37-7 3530-15-2 3731-59-7  
4318-79-0, 2,3,6-Pyridinetriamine 4362-86-1 4362-88-3 4568-71-2  
4635-08-9 4705-40-2 5051-62-7 5304-34-7 5418-95-1,  
2-Guanidinobenzimidazole 6274-00-6 6284-40-8, Meglumine 6421-06-3D,  
alkyl derivs., reaction with methylglyoxal hydrazone 6928-12-7  
7005-37-0 7467-00-7 7478-09-3 7684-18-6 13754-19-3,  
4,5-Diaminopyrimidine 13958-86-6 15579-63-2 15965-79-4 15970-40-8  
15970-41-9 15970-42-0 16060-65-4, 4-Guanidinobenzoic acid  
16311-69-6 16461-98-6, 1H-Pyrazole-3,4-diamine 18413-26-8  
18543-14-1 21440-72-2 21532-07-0 23899-73-2, 4,5-Diamino-2-hydroxy-  
pyrimidine 24043-51-4 24638-29-7 28020-38-4 28299-33-4D,  
Imidazoline, reaction with methylglyoxal hydrazone 28491-52-3  
29540-87-2, 1,2-Diaminobenzimidazole 33259-72-2, 6-Methyl-2,3-  
pyridinediamine 33631-04-8 36286-75-6 36684-18-1,  
Benzenecarbohydrazonic acid 1-methylhydrazide 38104-45-9,  
4H-1,2,4-Triazole-3,4-diamine 38304-91-5 40994-01-2 41230-93-7  
41927-05-3 44976-13-8 45157-68-4 49851-29-8 50850-16-3  
51565-03-8 52057-97-3 52197-73-6 52534-90-4, 1H-Imidazole-1,2-  
diamine 52559-11-2, 2,3,4-Pyridinetriamine 52602-70-7,  
4,5-Diamino-2,6-dimethylpyrimidine 53929-59-2, 4-Methyl-2,3-  
diaminopyridine 54016-70-5 56040-88-1 57132-40-8 57168-49-7  
57168-62-4 59352-90-8 60882-71-5 60882-72-6 61544-06-7  
62230-47-1, 4- Methylbenzamidrazone 62230-48-2 62230-49-3  
62230-50-6 64609-73-0 65873-85-0 69839-81-2 74385-09-4  
76430-86-9 79787-65-8 81539-69-7 84770-84-3 85128-73-0  
85561-97-3, 1H-Benzimidazole-2,5-diamine 87533-31-1 87533-39-9  
87533-43-5 87533-71-9 87910-71-2 88512-67-8 88512-68-9  
89790-89-6 89790-90-9 89790-91-0 89790-92-1 89790-95-4

89790-97-6 89790-98-7 89790-99-8 89791-00-4 89791-01-5  
 89791-02-6 89791-03-7 89791-04-8 89791-05-9 89791-06-0  
 90226-03-2 90833-87-7 97029-07-7 97380-14-8 98088-56-3  
 98526-41-1 103956-09-8, 3,4-Diaminobenzhydrazide 104025-75-4  
 104025-76-5 104096-90-4 106306-98-3 107867-51-6 111336-59-5  
 111336-60-8 111336-61-9 111928-66-6 114087-45-5 114087-65-9  
 122128-83-0 123272-54-8 123272-55-9 123272-59-3 123272-61-7  
 123272-67-3 123272-68-4 126824-12-2 126937-28-8 127356-16-5  
 127356-26-7 127356-27-8 127701-75-1 132026-22-3 132026-41-6  
 132091-96-4 132416-79-6 135047-60-8 136610-34-9 138650-05-2  
 138650-06-3 138650-07-4 144977-09-3 144977-09-3D, reaction with  
 methylglyoxal hydrazone 144977-11-7 144977-14-0 144977-16-2  
 144977-18-4 144977-20-8 144977-22-0 144977-24-2 144977-26-4  
 144977-28-6 144977-30-0 144977-32-2 144977-34-4 144977-36-6  
 144977-38-8 145703-67-9 145703-70-4 155601-17-5 157169-65-8,  
 Benzenecarboximidic acid 1-methylhydrazide 159356-41-9 165596-41-8  
 173177-21-4 173177-22-5 173177-24-7 173177-25-8 173177-27-0  
 175700-80-8 175700-82-0 175700-84-2 175700-86-4 177960-21-3  
 177960-22-4 177960-38-2 177960-55-3 181069-78-3 181069-79-4  
**181069-80-7** 181069-81-8 181069-82-9 181069-83-0  
**181069-84-1** 181069-85-2 181069-86-3 181069-89-6  
 181069-90-9 181069-91-0 181069-92-1 181069-93-2 181069-95-4  
 181069-96-5 181069-98-7 181069-99-8 181070-00-8 181070-05-3  
 181070-06-4 181070-07-5 181070-08-6 181070-09-7 181070-10-0  
 181070-11-1 181070-12-2 181070-13-3 181070-14-4 181070-72-4  
 181147-18-2 181147-20-6 181147-21-7


(inhibition of 3-deoxyglucosone and  $\alpha$ -dicarbonyl sugars in skin and therapeutic uses for oxidative stress related diseases)

IT **181069-80-7 181069-84-1**

(inhibition of 3-deoxyglucosone and  $\alpha$ -dicarbonyl sugars in skin and therapeutic uses for oxidative stress related diseases)

RN 181069-80-7 USPATFULL


CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, bromide (9CI) (CA INDEX NAME)



● Br<sup>-</sup>

RN 181069-84-1 USPATFULL

CN Thiazolium, 3-[2-(4-bromophenyl)-2-oxoethyl]-4,5-dimethyl-, bromide (9CI) (CA INDEX NAME)



● Br<sup>-</sup>

L9 ANSWER 3 OF 6 USPATFULL on STN

AB The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises a thiazolium compound capable of inhibiting, and to some extent reversing, the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:308308 USPATFULL

TITLE: Preventing and reversing advanced glycosylation endproducts

INVENTOR(S): Cerami, Anthony, Shelter Island, NY, United States  
 Ulrich, Peter C., Old Tappan, NJ, United States  
 Wagle, Dilip R., Valley Cottage, NY, United States  
 Hwang, San-Bao, Sudbury, MA, United States  
 Vasan, Sara, Yonkers, NY, United States

PATENT ASSIGNEE(S): Egan, John J., New York City, NY, United States  
 Alteon Inc., Ramsey, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 38330	E1	20031125
	US 5656261		19970812 (Original)
APPLICATION INFO.:	US 1999-373345		19990812 (9)
	US 1995-375155		19950118 (Original)
DOCUMENT TYPE:	Reissue		

DELACROIX

FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: McKane, Joseph K.  
 ASSISTANT EXAMINER: Sackey, Ebenezer  
 LEGAL REPRESENTATIVE: Elrifi, Ph.D., Ivor R., Golden, Matthew J., Mintz,  
 Levin, Cohn, Ferris, Glovsky & Popeo, P.C.  
 NUMBER OF CLAIMS: 234  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 1970

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CLM What is claimed is:

153. A composition adapted for **ocular** administration comprising one or more compounds selected from compounds of the formula: ##STR26## wherein R.sup.1 and R.sup.2 are independently hydrogen, . . .

154. The **ocular** composition of claim 153 wherein X is a halide, tosylate, methanesulfonate or mesitylenesulfonate ion.

155. The **ocular** composition of claim 153 wherein X is a halide ion.

156. The **ocular** composition of claim 153 wherein Z is hydrogen.

157. The **ocular** composition of claim 153, wherein, when R is aryl, at least one of R.sup.1 and R.sup.2 is other than hydrogen. . .

158. The **ocular** composition of claim 157 wherein Z is hydrogen.

159. The **ocular** composition of claim 158 wherein R is aryl.

160. The **ocular** composition of claim 158 wherein said compound is a 3-(2-phenyl-2-oxoethyl)thiazolium.

161. The **ocular** composition of claim 158 wherein said compound is a 3-(2-phenyl-2-oxoethyl)-4-methylthiazolium.

162. The **ocular** composition of claim 158 wherein said compound is a 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium.

163. The **ocular** composition of claim 158 wherein said compound is 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium bromide.

164. The **ocular** composition of claim 158 wherein said compound is a 3-(2-phenyl-2-oxoethyl)-5-methylthiazolium.

165. The **ocular** composition of claim 158 wherein said compound is a 3-(2-phenyl-2-oxoethyl)-benzothiazolium.

166. The **ocular** composition of claim 153 wherein Y is a 2-amino-2-oxoethyl group.

167. The **ocular** composition of claim 166 wherein said compound is a 3-(2-amino-2-oxoethyl)-4-methylthiazolium.

168. The **ocular** composition of claim 166 wherein said compound is a 3-(2,-amino-2-oxoethyl)benzothiazolium.



169. The **ocular** composition of claim 166 wherein said compound is a 3-(2-amino-2-oxoethyl)-4-methyl-5-(2-hydroxyethyl)thiazolium.

IT 4568-71-2P 5304-34-7P 6274-00-6P 7467-00-7P 7478-09-3P  
 16311-69-6P 52197-73-6P 53995-67-8P 54016-70-5P 57132-40-8P  
 57168-49-7P 57168-62-4P 61544-06-7P 74360-51-3P 74385-09-4P  
 87910-71-2P 97380-14-8P 121704-45-8P 132416-79-6P 138404-41-8P  
 159356-41-9P 181069-78-3P 181069-79-4P **181069-80-7P**  
 181069-81-8P 181069-82-9P 181069-83-0P **181069-84-1P**  
 181069-85-2P 181069-86-3P 181069-89-6P 181069-90-9P 181069-91-0P  
 181069-92-1P 181069-93-2P 181069-95-4P 181069-96-5P 181069-98-7P  
 181069-99-8P 181070-00-8P 181070-03-1P 181070-04-2P 181070-05-3P  
 181070-06-4P 181070-07-5P 181070-08-6P 181070-09-7P 181070-10-0P  
 181070-11-1P 181070-12-2P 181070-13-3P 181070-14-4P 181070-15-5P  
 181070-16-6P 181070-18-8P 181070-22-4P 181070-24-6P 181070-25-7P  
 181070-26-8P 181070-27-9P 181070-28-0P 181070-29-1P 181070-30-4P  
 181070-31-5P 181070-33-7P 181070-35-9P 181070-36-0P 181070-37-1P  
 181070-38-2P 181070-39-3P 181070-40-6P 181070-41-7P 181070-43-9P  
 181070-44-0P 181070-46-2P 181070-48-4P 181070-49-5P 181070-50-8P  
 181070-51-9P 181070-52-0P 181070-53-1P 181070-54-2P 181070-55-3P  
**181070-56-4P** 181070-57-5P 181070-58-6P 181070-59-7P  
 181070-60-0P 181070-61-1P 181070-62-2P 181070-63-3P 181070-64-4P  
 181070-65-5P 181070-66-6P 181070-67-7P 181070-68-8P 181070-69-9P  
 181070-70-2P 181070-71-3P 181070-72-4P 181070-74-6P 181147-74-0P


(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT **181069-80-7P 181069-84-1P 181070-56-4P**

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

RN 181069-80-7 USPATFULL

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, bromide (9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 181069-84-1 USPATFULL

CN Thiazolium, 3-[2-(4-bromophenyl)-2-oxoethyl]-4,5-dimethyl-, bromide (9CI) (CA INDEX NAME)


10/038,112



● Br<sup>-</sup>

RN 181070-56-4 USPATFULL

CN Thiazolium, 3-[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-oxoethyl]-4,5-dimethyl-, bromide (9CI) (CA INDEX NAME)



● Br<sup>-</sup>

L9 ANSWER 4 OF 6 USPATFULL on STN

AB Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DELACROIX

10/038,112

ACCESSION NUMBER: 2002:315102 USPATFULL  
TITLE: Method for treating fibrotic diseases or other indications ID  
INVENTOR(S): Egan, John J., New York, NY, UNITED STATES  
~~Wagle~~, Dilip, New York, NY, UNITED STATES  
~~Vasan~~, Sara, New York, NY, UNITED STATES  
~~Gall~~, Martin, Morristown, NJ, UNITED STATES  
~~Bell~~, Stanley, Narberth, PA, UNITED STATES  
~~LaVoie~~, Edmond J., Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177586	A1	20021128
APPLICATION INFO.:	US 2001-37447	A1	20011231 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-905188, filed on 13 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-218273P	20000713 (60)
	US 2001-296435P	20010606 (60)
	US 2001-259242P	20010102 (60)
	US 2000-259431P	<u>20001229</u> (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Allen Bloom, Esq., Dechert Price & Rhoads, P. O. Box 5218, Princeton, NJ, 08543  
NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2815  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . used to deliver the compound to the site where activity is desired; such as eye drops, gels and creams for **ocular** disorders.

SUMM . . . compositions of this invention include aqueous solutions comprising a safe and effective amount of a subject compound intended for topical **ocular** administration. Such compositions preferably comprise from about 0.01% to about 0.8% w/v of a subject compound, more preferably from about. . .

SUMM [0626] The compounds of the invention are administered by **ocular**, oral, parenteral, including, for example, using formulations suitable as eye drops. For **ocular** administration, ointments or droppable liquids may be delivered by **ocular** delivery systems known to the art such as applicators or eye droppers. Such compositions can include mucomimetics such as hyaluronic. . .

IT 393121-34-1D, salts  
(treating fibrotic diseases or other indications)

IT 356759-42-7P 356759-43-8P 356759-44-9P **356759-45-0P**  
**356759-46-1P 356759-47-2P** 356759-48-3P  
**356759-50-7P 356759-52-9P 356759-53-0P**  
392710-36-0P 392710-37-1P 392710-38-2P **393121-65-8P**  
393121-77-2P 393121-80-7P  
(treating fibrotic diseases or other indications)


IT 393121-34-1D, salts  
(treating fibrotic diseases or other indications)

RN 393121-34-1 USPATFULL

DELACROIX

10/038,112

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)




IT 356759-45-0P 356759-46-1P 356759-47-2P  
356759-50-7P 356759-52-9P 356759-53-0P  
393121-65-8P

(treating fibrotic diseases or other indications)

RN 356759-45-0 USPATFULL

CN Thiazolium, 3-[2-(4-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-46-1 USPATFULL

CN Thiazolium, 3-[2-(2-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-47-2 USPATFULL

CN Thiazolium, 3-[2-(3-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-50-7 USPATFULL

CN Thiazolium, 3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-52-9 USPATFULL

CN Thiazolium, 3-[2-(3,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-53-0 USPATFULL

CN Thiazolium, 3-[2-(2,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)


DELACROIX

10/038,112



● Br<sup>-</sup>

RN 393121-65-8 USPATFULL  
CN Thiazolium, 3-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, chloride  
(9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

L9 ANSWER 5 OF 6 USPATFULL on STN  
AB Provided, among other things, is a compound of the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:192111 USPATFULL

TITLE: Cyanomethyl substituted thiazoliums and imidazoliums  
and treatments of disorders associated with protein  
aging

INVENTOR(S): Wagle, Dilip R., New York, NY, UNITED STATES

DELACROIX

Fang, Sheng Ding, Mount Kisco, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103182	A1	20020801
	US 6610716	B2	20030826
APPLICATION INFO.:	US 2001-905035	A1	20010713 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-218273P	20000713 (60)
	US 2001-296435P	20010606 (60)
	US 2001-259242P	20010102 (60)
	US 2000-259431P	<u>20001229</u> (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DECHERT, P.O. Box 5218, Princeton, NJ, 08543	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1895	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . used to deliver the compound to the site where activity is desired; such as eye drops, gels and creams for **ocular** disorders.

SUMM . . . compositions of this invention include aqueous solutions comprising a safe and effective amount of a subject compound intended for topical **ocular** administration. Such compositions preferably comprise from about 0.01% to about 0.8% w/v of a subject compound, more preferably from about . . .

SUMM [0149] The compounds of the invention are administered by **ocular**, oral, parenteral, including, for example, using formulations suitable as eye drops. For **ocular** administration, ointments or droppable liquids may be delivered by **ocular** delivery systems known to the art such as applicators or eye droppers. Such compositions can include mucomimetics such as hyaluronic. . .

IT **393121-34-1D**, salts  
(treating fibrotic diseases or other indications)  
IT 356759-42-7P 356759-43-8P 356759-44-9P **356759-45-0P**  
**356759-46-1P 356759-47-2P** 356759-48-3P  
**356759-50-7P 356759-52-9P 356759-53-0P**  
392710-36-0P 392710-37-1P 392710-38-2P **393121-65-8P**  
393121-77-2P 393121-80-7P

(treating fibrotic diseases or other indications)


IT **393121-34-1D**, salts  
(treating fibrotic diseases or other indications)

RN 393121-34-1 USPATFULL

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



10/038,112




IT 356759-45-0P 356759-46-1P 356759-47-2P  
356759-50-7P 356759-52-9P 356759-53-0P  
393121-65-8P

(treating fibrotic diseases or other indications)

RN 356759-45-0 USPATFULL

CN Thiazolium, 3-[2-(4-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-46-1 USPATFULL

CN Thiazolium, 3-[2-(2-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-47-2 USPATFULL

CN Thiazolium, 3-[2-(3-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-50-7 USPATFULL

CN Thiazolium, 3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-52-9 USPATFULL

CN Thiazolium, 3-[2-(3,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-53-0 USPATFULL

CN Thiazolium, 3-[2-(2,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)


DELACROIX

10/038,112



● Br<sup>-</sup>

RN 393121-65-8 USPATFULL  
CN Thiazolium, 3-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, chloride  
(9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

L9 ANSWER 6 OF 6 USPATFULL on STN  
AB Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:133871 USPATFULL

TITLE: Method for treating fibrotic diseases or other

DELACROIX

indications IC  
 INVENTOR(S): Egan, Jack, New York, NY, UNITED STATES  
 Wagle, Dilip, Pune, INDIA  
 Vasan, Sara, New York, NY, UNITED STATES  
 Gall, Martin, Morristown, NJ, UNITED STATES  
 PATENT ASSIGNEE(S): Alteon, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068729	A1	20020606
APPLICATION INFO.:	US 2001-905188	A1	20010713 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-218273P	20000713 (60)
	US 2001-296435P	20010606 (60)
	US 2001-259242P	20010102 (60)
	US 2000-259431P	<u>20001229</u> (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: DECHERT, P.O. Box 5218, Princeton, NJ, 08543  
 NUMBER OF CLAIMS: 11  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2681

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . used to deliver the compound to the site where activity is desired; such as eye drops, gels and creams for **ocular** disorders,

SUMM . . . compositions of this invention include aqueous solutions comprising a safe and effective amount of a subject compound intended for topical **ocular** administration. Such compositions preferably comprise from about 0.01% to about 0.8% w/v of a subject compound, more preferably from about . . .

SUMM [0622] The compounds of the invention are administered by **ocular**, oral, parenteral, including, for example, using formulations suitable as eye drops. For **ocular** administration, ointments or droppable liquids may be delivered by **ocular** delivery systems known to the art such as applicators or eye droppers. Such compositions can include mucomimetics such as hyaluronic. . . .


IT **393121-34-1D**, salts  
 (treating fibrotic diseases or other indications)  
 IT 356759-42-7P 356759-43-8P 356759-44-9P **356759-45-0P**  
**356759-46-1P 356759-47-2P** 356759-48-3P  
**356759-50-7P 356759-52-9P 356759-53-0P**  
 392710-36-0P 392710-37-1P 392710-38-2P **393121-65-8P**  
 393121-77-2P 393121-80-7P

(treating fibrotic diseases or other indications)  
 IT **393121-34-1D**, salts  
 (treating fibrotic diseases or other indications)

RN 393121-34-1 USPATFULL

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)

10/038,112



IT 356759-45-0P 356759-46-1P 356759-47-2P


356759-50-7P 356759-52-9P 356759-53-0P

393121-65-8P

(treating fibrotic diseases or other indications)

RN 356759-45-0 USPATFULL

CN Thiazolium, 3-[2-(4-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-46-1 USPATFULL

CN Thiazolium, 3-[2-(2-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-47-2 USPATFULL

CN Thiazolium, 3-[2-(3-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-50-7 USPATFULL

CN Thiazolium, 3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-52-9 USPATFULL

CN Thiazolium, 3-[2-(3,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)



● Br<sup>-</sup>


RN 356759-53-0 USPATFULL

CN Thiazolium, 3-[2-(2,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX




10/038,112



● Br<sup>-</sup>

RN 393121-65-8 USPATEFULL

CN Thiazolium, 3-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, chloride  
(9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

DELACROIX

10/038,112

FILE 'HCAPLUS' ENTERED AT 21:24:29 ON 07 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 21:24:29 ON 07 JUN 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 21:24:29 ON 07 JUN 2004

FILE 'BIOSIS' ENTERED AT 21:24:29 ON 07 JUN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 21:24:29 ON 07 JUN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s 13

L4 73 L3

=> s 14 and glaucom?

L5 5 L4 AND GLAUCOM?

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 5 DUP REM L5 (0 DUPLICATES REMOVED)

=> d 16 abs ibib kwic hitstr 1-5

L6 ANSWER 1 OF 5 USPATFULL on STN

AB Provided is a method of treating or ameliorating an indication of the invention in an animal, including a human, by administering an effective amount of a compound of the formula I: ##STR1##

wherein R.sup.1, R.sup.2, M, X and Z are as described supra. Also provided are certain imidazolium compounds and pharmaceutical compositions containing the imidazolium compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:251637 USPATFULL

TITLE: Method for treating fibrotic diseases or other indications with imidazolium agents

INVENTOR(S): Wagle, Dilip, Pune, INDIA  
Vasan, Sara, New York, NJ, UNITED STATES  
Gall, Martin, Morristown, NJ, UNITED STATES

PATENT ASSIGNEE(S): Alteon, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176426	A1	20030918
APPLICATION INFO.:	US 2003-354952	A1	20030130 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-905188, filed on 13 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-38112, filed on 31 Dec 2001, PENDING		

NUMBER	DATE
-----	-----

DELACROIX

PRIORITY INFORMATION: US 2001-296435P 20010606 (60)  
 US 2000-218273P 20000713 (60)  
 US 2001-259242P 20010102 (60)  
 US 2000-259431P 20001229 (60)  
 US 2001-307418P 20010724 (60)  
 US 2001-296257P 20010606 (60)  
 US 2000-259426P 20001229 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: ALLEN BLOOM, C/O DECHERT, PRINCETON PIKE CORPORATION  
 CENTER, P.O. BOX 5218, PRINCETON, NJ, 08543-5218

NUMBER OF CLAIMS: 20  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2157

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM [0102] Treatment of **Glaucoma** and Improving Ocular Accomodation  
 SUMM [0104] Ophthalmologic disorders in diabetes include opacification and  
**glaucoma**. As the occurrence of these indications is correlated  
 with the persistent hyperglycemia of the disease. Although the incidence  
 of **glaucoma** is significant in diabetic populations,  
**glaucoma** affects a substantial portion of the general aging  
 population as well.

SUMM [0105] Primary open angle **glaucoma** occurs in approximately 4%  
 of diabetics compared to 1.8% of the general population. The reasons for  
 the increase in intraocular pressure that is observed in this disorder  
 are not completely understood. The increase in intraocular pressure that  
 characterizes **glaucoma** is likely caused by an impairment in  
 the drainage of fluid from the eye at the trabecular meshwork since  
 trabeculectomy. . . .

SUMM . . . present invention, methods for administering pharmaceutical  
 compositions containing certain compounds have been developed for  
 reducing the intraocular pressure associated with **glaucoma**.  
 These agents are substituted imidazolium agents as shown in the Summary  
 section above.

SUMM . . . a method is provided for the treatment of an animal, preferably  
 a mammal, preferably a human with ophthalmologic disorders including  
**glaucoma** and reduced accommodation. Briefly the method of the  
 present invention provides for a method of treatment of mammals with  
**glaucoma** or reduced accommodation that can be caused by age or  
 certain age-related diseased states such as diabetes. The method  
 provides. . . .

SUMM [0112] To treat **glaucoma** or reduced accommodation, and their  
 associated symptoms by administration of an effective amount of a  
 pharmaceutical compound will be recognized. . . .

SUMM [0114] In treating **glaucoma**, agents of the inventions can be  
 administered concurrently or in a combined formulation with one or more  
 $\alpha$ 2-selective adrenergic agonists, . . . .

SUMM . . . as those described here. See, copending U.S. patent application  
 Ser. No. 10/038,112, filed Dec. 31, 2001 for "Methods for Treating  
**Glaucoma** I," ("the '112 application," which is hereby  
 incorporated by reference).

IT 392710-36-0P **393121-34-1DP**, salts 393121-77-2P,  
 3-[2-(1-Pyrrolidinyl)-2-oxoethyl]-1,2-dimethylimidazolium chloride  
 393121-80-7P, 1-Butyl-3-aminoimidazolium mesitylenesulfonate  
 602279-69-6P 602279-70-9P 602279-71-0DP, salts 602279-72-1DP, salts  
 602279-73-2DP, salts 602279-74-3DP, salts  
 (AGE inhibitor; preparation of imidazolium AGE receptor inhibitors for



treating fibrotic diseases or other indications)

IT 393121-34-1DP, salts


(AGE inhibitor; preparation of imidazolium AGE receptor inhibitors for treating fibrotic diseases or other indications)

RN 393121-34-1 USPATFULL

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN  
GI

I



II

AB Provided is a method of decreasing intraocular pressure or improving ocular accommodation comprising administering I [R1-2 = H, acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxy carbonyl, etc.; Z = H, alkyl, Ar-CH<sub>2</sub>, NR<sub>3</sub>R<sub>4</sub>, etc.; R<sub>3</sub>-4 = H, alkyl, Ar, Ar-alkyl; Ar = (hetero)aryl; Y = amino, CHR<sub>5</sub>R<sub>6</sub>; R<sub>5</sub> = H, alkyl, cycloalkyl, alkenyl, alkynyl, aminoalkyl, etc.; R<sub>6</sub> = H, alk(en/yn)yl, cyano, aryl/heterocycle, etc.; Q = N, O, S; M is absent when Q = O, S; M = alkyl, vinyl, allyl, Y; X = pharmaceutically acceptable anion]. Examples include, 11 compds., effect of example compds. on outflow facility primates, drug penetration studies on intact cornea (rabbit, monkey), effect of compds. on i.m. pilocarpine-stimulated accommodative response (monkey) and the ability of test compds. to inhibit crosslinking (and reverse already formed cross linking) of glycated serum albumin to rat tail tendon collagen (which prevent outflow). For instance, 2-Chloro-1-phenylethanol (preparation given) was used to alkylate 4,5-dimethylthiazole (neat, 135°, 28 h) to afford II (9.7%) as prisms, mp 201-203°. I are useful in the treatment/prevention of **glaucoma**.

ACCESSION NUMBER: 2002:521491 HCAPLUS

DOCUMENT NUMBER: 137:78956

TITLE: Synthesis of thiazolium and imidazolium salts and use in treating **glaucoma**

INVENTOR(S): Egan, John J.; Wagle, Dilip; Vasan, Sara; Gall, Martin; Bell, Stanley C.; Lavoie, Edmond J.

DELACROIX

10/038,112

PATENT ASSIGNEE(S): Alteon, Inc., USA  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053158	A1	20020711	WO 2001-US49550	20011228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1353669	A1	20031022	EP 2001-988353	20011228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-259426P	P 20001229
			US 2001-296257P	P 20010606
			US 2001-307418P	P 20010724
			WO 2001-US49550	W 20011228
OTHER SOURCE(S): MARPAT 137:78956				
TI	Synthesis of thiazolium and imidazolium salts and use in treating <b>glaucoma</b>			
AB	. . . 4,5-dimethylthiazole (neat, 135°, 28 h) to afford II (9.7%) as prisms, mp 201-203°. I are useful in the treatment/prevention of <b>glaucoma</b> .			
ST	intraocular pressure <b>glaucoma</b> thiazole imidazole thiazolium imidazolium prepn accommodation			
IT	Antiglaucoma agents <b>Glaucoma</b> (disease) Human (synthesis of thiazolium and imidazolium salts as antiglaucoma agents)			
IT	356759-42-7P 356759-43-8P 356759-44-9P <b>356759-45-0P</b> <b>356759-46-1P 356759-47-2P</b> 356759-48-3P <b>356759-50-7P 356759-52-9P 356759-53-0P</b> 392710-36-0P 392710-37-1P 392710-38-2P <b>393121-65-8P</b> 393121-77-2P 393121-80-7P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (antiglaucoma agent; synthesis of thiazolium and imidazolium salts as antiglaucoma agents)			
IT	<b>356759-45-0P 356759-46-1P 356759-47-2P</b> <b>356759-50-7P 356759-52-9P 356759-53-0P</b> <b>393121-65-8P</b> RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (antiglaucoma agent; synthesis of thiazolium and imidazolium salts as antiglaucoma agents)			

DELACROIX

10/038,112

RN 356759-45-0 HCAPLUS


CN Thiazolium, 3-[2-(4-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)



● Br<sup>-</sup>

RN 356759-46-1 HCAPLUS

CN Thiazolium, 3-[2-(2-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-47-2 HCAPLUS

CN Thiazolium, 3-[2-(3-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-50-7 HCAPLUS

CN Thiazolium, 3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-52-9 HCAPLUS

CN Thiazolium, 3-[2-(3,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)


DELACROIX

10/038,112



● Br<sup>-</sup>

RN 356759-53-0 HCAPLUS  
CN Thiazolium, 3-[2-(2,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 393121-65-8 HCAPLUS  
CN Thiazolium, 3-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, chloride  
(9CI) (CA INDEX NAME)

DELACROIX





● Cl<sup>-</sup>

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 USPATFULL on STN

AB In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:330330 USPATFULL

TITLE: Method and composition for rejuvenating cells, tissues organs, hair and nails

INVENTOR(S): Ulrich, Peter C., Portland, OR, UNITED STATES  
Fang, Sheng Ding, Mount Kisco, NY, UNITED STATES  
Brines, Michael L., Woodbridge, CT, UNITED STATES  
Xie, Qiao-Wen, Yonkers, NY, UNITED STATES  
Cerami, Anthony, Sleepy Hollow, NY, UNITED STATES


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002188015	A1	20021212
APPLICATION INFO.:	US 2002-72712	A1	20020207 (10)

DELACROIX

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-267226P	<u>20010207</u> (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DREIER & BARITZ LLP, 499 PARK AVENUE, 20TH FLOOR, NEW YORK, NY, 10022	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3338	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
SUMM . . .	degenerative	Gonadal failure
	Diabetes-related	Hormone resistance
		Increased diffusion
Reproductive	Age-related, degenerative	Infertility
	Vascular (atherosclerosis-related)	Infertility
	Diabetes-related	Infertility
Ophthalmic	Age-related, degenerative	Presbyopia
		<b>Glaucoma</b>
	Vascular (atherosclerosis-related)	Macular degeneration
	(age-related)	
	Diabetes-related	Diabetic retinopathy
Hearing	Age-related, degenerative	Presbycusis
	Vascular (atherosclerosis-related)	Hearing loss
	Diabetes-related	Senso-neuronal hearing
loss		
Renal	Age-related, . . .	
DETD	Treatment of Age-related Eye Diseases: <b>Glaucoma</b> and Presbyopia	
DETD	[0421] A. <b>Glaucoma</b>	
DETD	[0422] <b>Glaucoma</b> is a leading cause of blindness. There are four major types of <b>glaucoma</b> :	
DETD	[0423] open angle or chronic <b>glaucoma</b>	
DETD	[0424] closed angle or acute <b>glaucoma</b>	
DETD	[0425] congenital <b>glaucoma</b>	
DETD	[0426] secondary <b>glaucoma</b>	
DETD	[0427] Open angle or chronic <b>glaucoma</b> is by far the most common type. In chronic <b>glaucoma</b> the outflow (Schlemm canal) of the aqueous humor is blocked. Although the precise mechanisms leading to outflow blockage have not been established, the occurrence of chronic <b>glaucoma</b> is associated with age above 45 years and diabetes. It is believed that decreased deformability and diffusional characteristics of the . . .	
DETD	[0428] In an embodiment of the present invention, a patient with diagnosed open angle <b>glaucoma</b> is treated with a medicament containing a composition of the present invention in an amount sufficient to exert clinical effectiveness.. . .	
IT	1094-77-5P 6274-04-0P 31410-05-6P 55643-70-4P 61821-90-7P	
	446839-32-3P 446839-34-5P 446839-36-7P 446839-38-9P 446839-40-3P	
	446839-41-4P 446839-42-5P 446839-43-6P 446839-45-8P 446839-46-9P	
	446839-47-0P 446839-48-1P 446839-49-2P 446839-50-5P 446839-51-6P	
	446839-52-7P 446839-53-8P 446839-54-9P 446839-55-0P	
	<b>446839-56-1P</b> 446839-57-2P 446839-58-3P 446839-59-4P	
	446839-60-7P 446839-61-8P 446839-62-9P 446839-63-0P 446839-64-1P	
	446839-65-2P 446839-66-3P 446839-72-1P 446839-73-2P 446839-74-3P	
	446839-75-4P 446839-76-5P 446839-77-6P	
	(preparation of azoles, azines and salts thereof for rejuvenating cells,	


10/038,112

tissues, organs, hair and nails)  
IT 81466-85-5 **341028-37-3** 446839-78-7  
(preparation of azoles, azines and salts thereof for rejuvenating cells,  
tissues, organs, hair and nails)  
IT **446839-56-1P**  
(preparation of azoles, azines and salts thereof for rejuvenating cells,  
tissues, organs, hair and nails)  
RN 446839-56-1 USPATFULL  
CN Thiazolium, 2-(1-hydroxyethyl)-4,5-dimethyl-3-(2-oxo-2-phenylethyl)-,  
bromide (9CI) (CA INDEX NAME)



● Br<sup>-</sup>

IT **341028-37-3**  
(preparation of azoles, azines and salts thereof for rejuvenating cells,  
tissues, organs, hair and nails)  
RN 341028-37-3 USPATFULL  
CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, chloride (9CI) (CA  
INDEX NAME)



● Cl<sup>-</sup>

L6 ANSWER 4 OF 5 USPATFULL on STN  
AB Provided is a method of treating or ameliorating or preventing  
**glaucoma**, decreasing intraocular pressure or improving or  
ameliorating ocular accommodation in an animal, including a human  
comprising administering an intraocular pressure decreasing or  
accommodation improving amount of a compound of the formula I:

DELACROIX

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:288123 USPATFULL  
 TITLE: Method for treating **glaucoma** IC  
 INVENTOR(S): Egan, John J., New York, NY, UNITED STATES  
 Wagle, Dilip, New York, NY, UNITED STATES  
 Vasan, Sara, New York, NY, UNITED STATES  
 Gall, Martin, Morristown, NJ, UNITED STATES  
 Bell, Stanley, Narberth, PA, UNITED STATES  
 LaVoie, Edmond Joseph, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160993	A1	20021031
APPLICATION INFO.:	US 2001-38112	A1	20011231 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-307418P	20010724 (60)
	US 2001-296257P	20010606 (60)
	US 2000-259426P	<u>20001229</u> (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALLEN BLOOM, C/O DECHERT, PRINCETON PIKE CORPORATION CENTER, P.O. BOX 5218, PRINCETON, NJ, 08543-5218	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2653	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Method for treating **glaucoma** IC  
 AB Provided is a method of treating or ameliorating or preventing **glaucoma**, decreasing intraocular pressure or improving or ameliorating ocular accommodation in an animal, including a human comprising administering an intraocular pressure. . .  
 SUMM [0002] The present invention relates to methods for treating **glaucoma** or improving accommodation (i.e. the process by which the eye adjusts for vision at different distances), and to compounds and. . . in such treating. In one aspect, the present invention relates to a method of decreasing the intraocular pressure caused by **glaucoma**.  
 SUMM [0004] Ophthalmologic disorders in diabetes include opacification and **glaucoma**. As the occurrence of these indications is correlated with the persistent hyperglycemia of the disease. Although the incidence of **glaucoma** is significant in diabetic populations, **glaucoma** affects a substantial portion of the general aging population as well.  
 SUMM [0005] Primary open angle **glaucoma** occurs in approximately 4% of diabetics compared to 1.8% of the general population. The reasons for the increase in intraocular pressure that is observed in this disorder are not completely understood. The increase in intraocular pressure that characterizes **glaucoma** is likely caused by an impairment in the drainage of fluid from the eye at the trabecular meshwork since trabeculectomy. . .  
 SUMM [0008] New strategies for pharmaceutical intervention in the treatment

DELACROIX

of **glaucoma** based upon new mechanisms of action need to be identified. In addition, pharmaceutical agents that decrease the intraocular pressure associated with **glaucoma** are needed. Also, the methods of improving accommodation provided by the invention allow one to avoid costly and burdensome optical. . .

SUMM [0009] In one embodiment, the invention relates to a method of treating or ameliorating or preventing **glaucoma**, decreasing intraocular pressure or improving or ameliorating ocular accommodation in an animal, including a human comprising administering an intraocular pressure. .

DETD . . . a method is provided for the treatment of an animal, preferably a mammal, preferably a human with ophthalmologic disorders including **glaucoma** and reduced accommodation. Briefly the method of the present invention provides for a method of treatment of mammals with **glaucoma** or reduced accommodation that can be caused by age or certain age-related diseased states such as diabetes. The method provides. . .

DETD [0084] Primary open angle **glaucoma** is characterized by an increase in intraocular pressure. The condition of open angle **glaucoma** is characterized by an increase in the pressure within a person's eye or eyes, called the intraocular pressure. The normal. .

DETD . . . present invention, methods for administering pharmaceutical compositions containing certain compounds have been developed for reducing the intraocular pressure associated with **glaucoma**. These agents are either substituted thiazolium, oxazolium, or imidazolium agents as shown in the Summary section above.

DETD [0569] To treat **glaucoma** or reduced accommodation, and their associated symptoms by administration of an effective amount of a pharmaceutical compound will be recognized. . .

DETD [0570] In treating **glaucoma**, agents of the inventions can be administered concurrently or in a combined formulation with one or more  $\alpha$ .sub.2-selective adrenergic agonists,. . .

IT 393121-34-1D, salts

(treating fibrotic diseases or other indications)

IT 356759-42-7P 356759-43-8P 356759-44-9P 356759-45-0P

356759-46-1P 356759-47-2P 356759-48-3P

356759-50-7P 356759-52-9P 356759-53-0P

392710-36-0P 392710-37-1P 392710-38-2P 393121-65-8P

393121-77-2P 393121-80-7P


(treating fibrotic diseases or other indications)

IT 393121-34-1D, salts

(treating fibrotic diseases or other indications)

RN 393121-34-1 USPATFULL

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



DELACROIX


10/038,112

IT 356759-45-0P 356759-46-1P 356759-47-2P  
356759-50-7P 356759-52-9P 356759-53-0P  
393121-65-8P

(treating fibrotic diseases or other indications)

RN 356759-45-0 USPATFULL


CN Thiazolium, 3-[2-(4-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)



● Br<sup>-</sup>

RN 356759-46-1 USPATFULL

CN Thiazolium, 3-[2-(2-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-47-2 USPATFULL

DELACROIX

10/038,112


CN Thiazolium, 3-[2-(3-hydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)



● Br<sup>-</sup>

RN 356759-50-7 USPATFULL

CN Thiazolium, 3-[2-(2,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 356759-52-9 USPATFULL

CN Thiazolium, 3-[2-(3,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)

DELACROIX


10/038,112



● Br<sup>-</sup>

RN 356759-53-0 USPATFULL

CN Thiazolium, 3-[2-(2,5-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, bromide  
(9CI) (CA INDEX NAME)




● Br<sup>-</sup>

RN 393121-65-8 USPATFULL

CN Thiazolium, 3-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]-4,5-dimethyl-, chloride  
(9CI) (CA INDEX NAME)

DELACROIX





● Cl<sup>-</sup>

L6 ANSWER 5 OF 5 USPATFULL on STN

AB Provided, among other things, is a method of treating, ameliorating or preventing certain fibrotic diseases or other indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I:

Het-Y (I)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:199136 USPATFULL

TITLE: Method for treating fibrotic diseases or other indications IVC

INVENTOR(S): Wagle, Dilip, New York, NY, UNITED STATES  
Gall, Martin, Morristown, NJ, UNITED STATES  
Bell, Stanley C., Narberth, PA, UNITED STATES  
LaVoie, Edmond J., Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107245	A1	20020808
APPLICATION INFO.:	US 2001-38117	A1	20011231 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296256P	20010606 (60)
	US 2001-259254P	20010102 (60)
	US 2000-259424P	20001229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALLEN BLOOM, C/O DECHERT, PRINCETON PIKE CORPORATION CENTER, P.O. BOX 5218, PRINCETON, NJ, 08543-5218	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	

DELACROIX

10/038,112

LINE COUNT: 1834

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . phases of the disease, continued abnormal vessel growth and scar tissue may cause serious problems such as retinal detachment and **glaucoma**. First agents are used to treat, prevent, reduce or ameliorate diabetic retinopathy. The agents can be administered by the methods. . .

IT 393121-34-1


(heterocyclic compds. for treatment of fibrotic diseases or other conditions)

IT 393121-34-1

(heterocyclic compds. for treatment of fibrotic diseases or other conditions)

RN 393121-34-1 USPATFULL

CN Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



=>

DELACROIX